Targeted Therapy Combines Superior Kidney Cancer Outcomes
- A new study from The University of texas MD Anderson Cancer Centre indicates that a combination therapy of lenvatinib and everolimus may significantly improve outcomes for patients with...
- Published October 19, 2025, the findings offer a potential new second-line treatment option and could guide future treatment decisions for those battling this aggressive form of kidney cancer.
- Clear-cell renal carcinoma (ccRCC) is the most common type of kidney cancer, accounting for approximately 85-90% of all kidney cancer diagnoses according to the American Cancer Society.
“`html
Lenvatinib Plus Everolimus Shows Promise for Advanced Kidney Cancer
Table of Contents
A new study from The University of texas MD Anderson Cancer Centre indicates that a combination therapy of lenvatinib and everolimus may significantly improve outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC) after immunotherapy has failed.
Published October 19, 2025, the findings offer a potential new second-line treatment option and could guide future treatment decisions for those battling this aggressive form of kidney cancer.
What is Clear-Cell Renal Carcinoma?
Clear-cell renal carcinoma (ccRCC) is the most common type of kidney cancer, accounting for approximately 85-90% of all kidney cancer diagnoses according to the American Cancer Society. It originates in the lining of the proximal convoluted tubule, a part of the kidney responsible for filtering waste.
Metastatic ccRCC, where the cancer has spread to other parts of the body, presents a significant clinical challenge. Immunotherapy has become a standard first-line treatment, but many patients eventually experiance disease progression, necessitating alternative therapies.
The LenCabo Trial: Key findings
The research, based on data from the LenCabo Phase 2 trial, focused on patients whose ccRCC had progressed after prior immunotherapy. The trial evaluated the combination of lenvatinib, a tyrosine kinase inhibitor, and everolimus, an mTOR inhibitor.
Researchers found that the lenvatinib plus everolimus combination led to improved outcomes compared to standard second-line treatments. while specific data points regarding overall survival and progression-free survival were not detailed in the source, the study suggests a “more meaningful benefit” for patients.
The study was presented at the European Society for Medical Oncology (ESMO) Congress in october 2025 according to the University of Texas MD Anderson Cancer Center.
How lenvatinib and Everolimus Work
Lenvatinib and everolimus target different pathways involved in cancer growth and progression:
- Lenvatinib: Blocks the activity of tyrosine kinases,proteins that play a role in blood vessel formation (angiogenesis) and tumor growth.
- Everolimus: Inhibits mTOR (mammalian target of rapamycin),a protein kinase that regulates cell growth,proliferation,and survival.
By combining these two drugs, researchers aimed to disrupt multiple pathways together, potentially leading to a more effective anti-cancer response.